combined digoxin and furosemide

PreclinicalSmall molecule

combined digoxin and furosemide is one of 13 small molecule programs targeting Plantar Wart. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plantar WartActive, not recruiting

Plantar WartPreclinical

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Plantar Wart

#DrugCompanyPhaseTrials

Zovirax

BBp Consulting, Inc

Approved

1 2

Aldara

BBausch Health Americas, Inc.

Approved

1 3

Salicylate

AAssistance Publique - Hôpitaux de Paris

Approved

1 4

CRYOTHERAPY

AAssistance Publique - Hôpitaux de Paris

Approved

1 5

Inomax

MMallinckrodt

Phase 2

1 6

Salicylic Acid

HHadassah Medical Organization

Phase 3

1 7

Blenoxane

Bristol-Myers Squibb

Preclinical

3 8

Potassium Hydroxide

SSohag University

Phase 3

1 9

Intralesional Acyclovir

RRiphah International University

Phase 3

1 10

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Plantar Wart1 trial

Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts

Unknown status·SSohag University·N/A·NCT05520658·60 enrolled

Efficacy1 trial

Efficacy of Intralesional Injection of Pentoxifylline, Platelet-Rich Plasma, and Combined Pentoxifylline With Platelet-Rich Plasma in Patients With Atrophic Acne Scars

Recruiting·SSohag University·N/A·NCT06319768·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for combined digoxin and furosemide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — combined digoxin and furosemide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for combined digoxin and furosemide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sohag University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSohag University

combined digoxin and furosemide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Plantar Wart1 trial

Efficacy1 trial

References

Drug Info

Quick Facts

Related News